ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib - PubMed
5 days ago
- #Osimertinib resistance
- #Molecular profiling
- #EGFR-mutant NSCLC
- ELIOS study (NCT03239340) focused on EGFR-mutant advanced NSCLC patients treated with first-line osimertinib.
- Acquired resistance mechanisms were analyzed using paired tumor biopsies pre-treatment and post-progression.
- Common resistance alterations included MET amplification (17%), CDKN2A/CDKN2B deletion (15%), MTAP deletion (13%), and EGFR C797S (13%).
- Proteogenomic analysis showed high TROP2 expression at baseline and post-progression, independent of genetic alterations.
- Tissue and plasma NGS demonstrated complementary roles, with 82% of post-progression samples showing potential resistance alterations.
- Findings highlight challenges in obtaining tissue biopsies, heterogeneous resistance mechanisms, and the need for broad-acting treatments.